Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pain 1Neurotoxicity Syndromes 1Hematologic Neoplasms 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 196Cisplatin 188Magnetic Resonance Spectroscopy 167Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 117Paclitaxel 112Oxaliplatin 110Biopsy 105venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 69sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Duloxetine Hydrochloride × Clear all
NCT04560673 2025-12-31

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

M.D. Anderson Cancer Center

Phase 2 Recruiting
380 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04970121 2024-09-25

Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy

The First Affiliated Hospital of Bengbu Medical University

Phase 2 Recruiting
100 enrolled

Pain

NCT06551051 2024-09-19

ADC-induced Neurotoxicity Treated With Duloxetine

Fudan University

Phase 2 Recruiting
37 enrolled

Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡